<DOC>
	<DOCNO>NCT00888940</DOCNO>
	<brief_summary>A Phase 2 Randomized Double-Blind Active-Controlled Study Subjects Exposed Cardio-pulmonary Bypass During Cardiac Surgery High Risk Bleeding</brief_summary>
	<brief_title>Outcomes Safety Trial Investigating Ecallantide 's Effect Reducing Surgical Blood Loss Volume Subjects High Risk Bleeding Exposed Cardio-pulmonary Bypass During Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Written inform consent ( study subject ) prior studyrelated procedure part normal medical care ; Male female age 18 85 year old , inclusive ; Planned cardiac surgery use cardiopulmonary bypass , one following procedure : repeat sternotomy ; surgery repair replace one valve ; combine CABG plus repair replacement least one valve If female , subject nonlactating , either : Not childbearing potential , defined postmenopausal least one year surgically sterile due bilateral tubal ligation , bilateral oophorectomy , hysterectomy ; Of childbearing potential pregnant confirm negative pregnancy test time screen ( base βsubunit HCG ) , practice barrier method birth control along one follow method : oral parenteral contraceptive three month prior study drug administration , vasectomized partner , abstinence sexual intercourse . Planned primary CABG , single valve repair replacement surgery , pump procedure ; Body weight &lt; 55 kg ; Planned hypothermia ( &lt; 28ºC ) ; Planned transfusion perioperative postoperative period ; Planned transfusion preoperatively donate autologous blood ; Female subject pregnant lactating ; Planned use desmopressin , lysine analog ( study medication ) , atrial natriuretic hormone recombinant activate Factor VII ; Planned use corticosteroid pump prime solution ; Ejection fraction &lt; 30 % within 90 day prior surgery ; Evidence myocardial infarction within 5 day prior surgery ; History stroke transient ischemic attack within 3 month prior surgery ; Hypotension heart failure require use inotropes mechanical device within 24 hour prior surgery ; Serum creatinine &gt; 2.0 mg/dL within 48 hour prior surgery ; Serum hepatic enzyme ( aspartate aminotransferase alanine aminotransferase ) 2.5 time upper limit normal applicable laboratory ; Hematocrit &lt; 32 % within 48 hour prior surgery ; Platelet count normal range applicable laboratory within 14 day prior surgery ; History , family history , bleed clot disorder ( e.g . von Willebrand 's Disease , idiopathic thrombocytopenia purpura ) thrombophilia antithrombin III deficiency Factor V Leiden mutation ; History heparininduced thrombocytopenia ; Prothrombin time ( PT ) and/or activate partial thromboplastin time ( aPTT ) &gt; 1.5 X normal range unless subject receive heparin within 24 hour test ; Serious intercurrent illness active infection ( e.g . endocarditis , sepsis , active malignancy require treatment ) ; Any previous exposure ecallantide ; Receipt investigational drug device 30 day prior participation current study ; Any condition , opinion investigator , may compromise safety compliance subject would preclude subject successful completion study ; Inability comply protocol duration study ; Known allergy agent expect used intraoperative postoperative period ; Administration : Eptifibatide within 6 hour prior surgery , Tirofiban hydrochloride within 6 hour prior surgery , ( Enoxaparin sodium lowmolecularweight heparin &lt; 24 hour prior surgery ) , Prasugrel within 10 day prior surgery , Clopidogrel within 3 day prior surgery , Ticlopidine within 7 day prior surgery , Abciximab within 5 day prior surgery , ( Bivalirudin , argatroban lepirudin within 6 hour prior surgery ) , ( Fondaparinux within 72 hour prior surgery ) , Chlorpromazine within 7 day prior surgery ( Prophylactic use permit prevention deep vein thrombosis . ) Planned use heparin bond bypass circuit ; Known allergy hypersensitivity tranexamic acid ingredient ; Disturbance color sense ; Evidence hematuria acute thromboses thromboembolic disease deep vein thrombosis , pulmonary embolism , vertebral vein thrombosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>